About
Titles
Hospital Resident
Biography
Theresa completed her medical education at Friedrich-Alexander-Universität Erlangen-Nürnberg in Germany. During medical school, she spent one year working with the Red Cross in Mexico and received a TRENAL Student Scholarship to complete one year of predoctoral clinical research in Nephrology at University Hospital Erlangen and Yale School of Medicine. Before starting her residency training, Theresa completed another two years of research with the Section of Thoracic Surgery, Department of Surgery at Yale School of Medicine focused on outcomes and disparities in thoracic oncology. She plans to become an academic surgeon specializing in thoracic surgical oncology.
Education & Training
- MD
- Friedrich-Alexander-Universität Erlangen-Nürnberg (2020)
Research
Overview
Medical Subject Headings (MeSH)
Thoracic Diseases; Thoracic Neoplasms
ORCID
0000-0001-8483-5758
Research at a Glance
Yale Co-Authors
Frequent collaborators of Theresa Ermer's published research.
Publications Timeline
A big-picture view of Theresa Ermer's research output by year.
Daniel Boffa, MD
Peter S. Aronson, MD
Felix Knauf, MD
Justin D. Blasberg, MD, MPH, FACS
Matthew Pichert, MD, MPH
Vincent Mase, MD, BS
17Publications
282Citations
Publications
2024
Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individualsAssociation of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer
Maduka R, Canavan M, Walters S, Ermer T, Zhan P, Kaminski M, Li A, Pichert M, Salazar M, Prsic E, Boffa D. Association of patient socioeconomic status with outcomes after palliative treatment for disseminated cancer. Cancer Medicine 2024, 13: e7028. PMID: 38711364, PMCID: PMC11074703, DOI: 10.1002/cam4.7028.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsOptimal quality of careQuality of carePatient socioeconomic statusAssociated with improved qualityAssociated with improved quality of lifeEnd-of-lifeUS cancer populationPalliative treatmentQuality of lifeCox proportional hazards modelsMultivariate logistic regressionInformed decision makingProportional hazards modelFacility characteristicsNon-HispanicAssociated with lower ratesInsurance payer statusImproving informed decision makingCancer populationSocioeconomic statusHispanic ethnicityTreatment usePayer statusBlack raceLogistic regression
2022
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy useEvaluation of gastroesophageal reflux disease and hiatal hernia as risk factors for lobectomy complications
Kaminski MF, Ermer T, Canavan M, Li AX, Maduka RC, Zhan P, Boffa DJ, Case MD. Evaluation of gastroesophageal reflux disease and hiatal hernia as risk factors for lobectomy complications. JTCVS Open 2022, 11: 327-345. PMID: 36172441, PMCID: PMC9510864, DOI: 10.1016/j.xjon.2022.05.017.Peer-Reviewed Original ResearchAltmetricConceptsGastroesophageal reflux diseaseHiatal herniaAtrial arrhythmiasPostoperative complicationsRisk factorsReflux diseaseAdverse eventsIntraoperative packed red blood cellsPacked red blood cellsYale-New Haven HospitalAcid suppressive therapyPredictors of complicationsBody mass indexLung cancer patientsNovel risk factorsSignificant risk factorsMultivariable regression modelsCardiopulmonary comorbiditiesPulmonary resectionRed blood cellsMedian agePreoperative evaluationMass indexMale sexSurgical approachAssociation Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. JAMA Network Open 2022, 5: e2219535. PMID: 35771575, PMCID: PMC9247736, DOI: 10.1001/jamanetworkopen.2022.19535.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNon-small cell lung cancerRenal cell carcinomaUse of immunotherapyFDA approvalImmunotherapy useCohort studyClinical trialsNovel therapiesStage IV non-small cell lung cancerMultivariable logistic regression modelingFirst checkpoint inhibitorCheckpoint inhibitor therapyNational Cancer DatabasePatients 20 yearsCell lung cancerSocioeconomic strataTreatment of patientsDrug Administration approvalLife-saving treatmentReceipt of immunotherapyLogistic regression modelingSocioeconomic characteristicsImmunotherapy administrationCheckpoint inhibitorsPatient characteristicsAssociation of Insurance Status and Extent of Organ Involvement With Survival Among Patients With Stage IV Cancer
Zhan PL, Canavan ME, Ermer T, Pichert MD, Li AX, Maduka RC, Boffa DJ. Association of Insurance Status and Extent of Organ Involvement With Survival Among Patients With Stage IV Cancer. JAMA Network Open 2022, 5: e2217581. PMID: 35713907, PMCID: PMC9206181, DOI: 10.1001/jamanetworkopen.2022.17581.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsRevisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasisUnderstanding the Implications of Medicaid Expansion for Cancer Care in the US
Ermer T, Walters SL, Canavan ME, Salazar MC, Li AX, Doonan M, Boffa DJ. Understanding the Implications of Medicaid Expansion for Cancer Care in the US. JAMA Oncology 2022, 8: 139-148. PMID: 34762101, DOI: 10.1001/jamaoncol.2021.4323.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsUS cancer populationCancer careMedicaid expansionCancer populationEligibility criteriaHealth policy initiativesHealth policy factorsOncology teamAffordable Care ActInsurance statusOncological careMedicaid coverageExpansion of MedicaidUninsured individualsCancer treatmentInsurance profileCareInterpretation of findingsPatient ProtectionHealth insuranceMedicaidCare ActSignificant changes
2021
The rural Uganda non-communicable disease (RUNCD) study: prevalence and risk factors of self-reported NCDs from a cross sectional survey
Siddharthan T, Kalyesubula R, Morgan B, Ermer T, Rabin TL, Kayongo A, Munana R, Anton N, Kast K, Schaeffner E, Kirenga B, Knauf F. The rural Uganda non-communicable disease (RUNCD) study: prevalence and risk factors of self-reported NCDs from a cross sectional survey. BMC Public Health 2021, 21: 2036. PMID: 34743687, PMCID: PMC8572568, DOI: 10.1186/s12889-021-12123-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSelf-reported hypertensionSelf-reported chronic diseasesNon-communicable Disease studyChronic disease informationRural Ugandan districtSelf-reported diseasesDiagnosis of diabetesCross-sectional surveyMiddle-income settingsBaseline demographicsMale sexKidney diseasePatient cohortResultsA totalHealth districtRisk factorsChronic diseasesDisease cohortHypertensionLower oddsNCD prevalenceAverage ageSectional surveyHealth statusDiseaseHigh Oxalate Concentrations Increase Risk for Sudden Cardiac Death in Dialysis Patients
Pfau A, Ermer T, Coca S, Tio M, Genser B, Reichel M, Finkelstein F, März W, Wanner C, Waikar S, Eckardt K, Aronson P, Drechsler C, Knauf F. High Oxalate Concentrations Increase Risk for Sudden Cardiac Death in Dialysis Patients. Journal Of The American Society Of Nephrology 2021, 32: 226-226. DOI: 10.1681/asn.20213210s1226a.Peer-Reviewed Original Research